Protein language model pseudolikelihoods capture features of in vivo B cell selection and evolution

Daphne van Ginneken[1], Anamay Samant[2], Karlis Daga-Krumins[1], Andreas Agrafiotis[2], Evgenios Kladis[2], Sai T. Reddy[2,3], Alexander Yermanos[1,2,3,*]

[1]Center for Translational Immunology, University Medical Center Utrecht, Lundlaan 6, Utrecht 3584EA, The Netherlands.
[2]Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, Basel 4058, Switzerland.
[3]Department of Pathology and Immunology, University of Geneva, 24 rue du General-Dufour, Geneva 1211, Switzerland.
*Corresponding author. Email: a.d.yermanos@umcutrecht.nl

Keywords

Protein Language Models, B cells, Antibodies, Repertoire, Somatic Hypermutation

Key points

- In contrast to previous in vitro work (Hie et al., 2024), we observe a negative correlation between PLM-generated sequence pseudolikelihood (SP) and binding affinity. This contrast can be explained by the inherent antibody germline bias posed by PLM training data and the difference between in vivo and in vitro settings.
- Our findings also reveal a considerable correlation between SPs and repertoire features such as the V-gene family, isotype, and the amount of somatic hypermutation (SHM). Moreover, labeled antigen-binding data suggested that SP is consistent with antigen-specificity and binding affinity.
- By reconstructing B cell lineage evolutionary trajectories, we detected predictable features of SHM using PLMs. We observe that SHMs are routinely among the most likely mutations suggested by PLMs and that mutating residues have lower absolute likelihoods than conserved residues.
- We demonstrate that the region of antibody sequence (CDR3 or full V(D)J) provided as input to the model, as well as the type of PLM used, influence the resulting SPs.

Abstract

B cell selection and evolution play crucial roles in dictating successful immune responses. Recent advancements in sequencing technologies and deep-learning strategies have paved the way for generating and exploiting an ever-growing wealth of antibody repertoire data. The self-supervised nature of protein language models (PLMs) has demonstrated the ability to learn complex representations of antibody sequences and has been leveraged for a wide range of applications including diagnostics, structural modeling, and antigen-specificity predictions. PLM-derived likelihoods have been used to improve antibody affinities in vitro, raising the question of whether PLMs can capture and predict features of B cell selection in vivo. Here, we explore how general and antibody-specific PLM-generated sequence pseudolikelihoods (SPs) relate to features of in vivo B cell selection such as expansion, isotype usage, and somatic hypermutation (SHM) at single-cell resolution. Our results demonstrate that the type of PLM and the region of the antibody input sequence significantly affect the generated SP. Contrary to previous in vitro reports, we observe a negative correlation between SPs and binding affinity, whereas repertoire features such as SHM, isotype usage, and antigen specificity were strongly correlated with SPs. By constructing evolutionary lineage trees of B cell clones from human and mouse repertoires, we observe that SHMs are routinely among the most likely mutations suggested by PLMs and that mutating residues have lower absolute likelihoods than conserved residues. Our findings highlight the potential of PLMs to predict features of antibody selection and further suggest their potential to assist in antibody discovery and engineering.

Introduction

B cells recognize and bind to a variety of antigenic structures through their highly diverse and specific B cell receptors (BCRs, secreted version antibodies). BCRs are composed of two identical heavy and light chains, which consist of the variable (V), diversity (D) (only for heavy chain), joining (J), and constant (C) gene segments. The heavy chain C gene segments classify BCRs into isotypes that enable further interactions with the host immune system (1). Initial BCR diversity is generated by rearrangements of the V(D)J gene segments (2). The junction of these segments forms the third complementarity-determining region (CDR3), which exhibits the highest degree of sequence variability and contributes the most to determining antigen specificity (3). Upon antigen encounter, B cells can undergo clonal expansion and affinity maturation, where iterative rounds of SHM introduce further sequence diversity in the BCR (4). Understanding the principles of B cell selection is essential to discovering and engineering high affinity broadly neutralizing antibodies for therapeutic purposes.

Recent advancements in deep sequencing and microfluidic techniques have made it possible to comprehensively profile B cells and their corresponding antibody repertoires, providing a quantitative framework to investigate features of B cell selection (5). The rapid increase of antibody repertoire sequencing experiments has generated a wealth of data, providing fundamental insights into B cell biology and advancing applications such as antibody discovery and vaccine profiling (6–10). Furthermore, paired full-length heavy and light chain sequence information can be recovered at single-cell resolution and combined with functional characterization via recombinant expression of antibodies of interest (7). Antibody sequences can thereby be linked to biophysical properties such as antigen specificity and binding affinity. Together, such experiments have helped elucidate how single-cell repertoire sequencing can be used for antibody discovery efforts (6,9) and also shed light into fundamental insights of B cell biology pertaining to epitope convergence (9) or how transcriptional phenotypes relate to binding affinity (11).

Inspired by the recent success of natural language processing, deep learning models have been leveraged to learn complex features of protein sequences. Protein language models (PLMs) utilize unsupervised masked language modeling and are trained on large repositories of sequences. PLM representations have effectively captured structural, functional, and evolutionary features of general protein sequences (general PLM) (12–15). In line with this success, antibody-specific PLMs, trained on the massive wealth of repertoire sequencing data, have been shown to capture unique features of antibody selection such as germline gene usage and SHM (16–19). Both general and antibody-specific PLMs have been used for tasks such as humanization, structural prediction, and affinity maturation (20–22).

The masked language objective of PLMs enable the extraction of per-residue likelihoods (RLs) when supplied with unseen sequences as input. This further allows for the computation of pseudolikelihoods for entire sequences (SPs), which has been used as a computationally efficient approximation of the likelihood for entire sequences (23). It was recently demonstrated that PLM-based RLs could be leveraged to improve antibody affinity, despite remaining agnostic to affinity labels during training (20). In this work, *in silico* mutagenesis of therapeutic antibodies was performed based on PLM-suggested mutations that increased RL. In another study, the same group demonstrated that augmenting a general PLM with structural information of the entire antibody-antigen complex, using the inverse folding likelihood, can guide artificial B cell evolution (24). It however remains unknown how PLM-based likelihoods relate to in vivo features of B cell selection and evolution.

Here, we leveraged general and antibody-specific PLMs on single-cell antibody repertoire sequencing data to explore the relationship between PLM-based likelihoods and features of in vivo B cell selection and evolution. We demonstrate that the region of antibody sequence provided as input to the model, as well as the type of PLM used, influence the resulting SPs. Our findings reveal a considerable correlation between SPs and repertoire features such as V-gene family, isotype, and SHM. By reconstructing lineage evolutionary trajectories, we detected predictable features of SHM using RLs. Moreover, labeled antigen-binding data suggested that SP is consistent with antigen-specificity and binding affinity. Our study emphasizes the potential of utilizing PLMs to explore in vivo B cell selection and illustrates the power of computational tools in facilitating therapeutic antibody discovery.

Results
Minor correlation of SPs from varying degrees of contextual information
To study the relationship between B cell repertoire selection and SPs at single-cell resolution, we leveraged four previously published B cell repertoire datasets in the context of immunization and infection, which also provided experimental measurements of antibody specificity and affinity (Figure 1A). From these datasets, we utilized samples from five mice and five human individuals in total. The mouse dataset contained BCR sequences from bone marrow plasma cells (PCs) of five mice immunized with model antigen ovalbumin (OVA) (9), hereafter referred to as Mouse1-5. The first human sample (Individual1) consisted of blood-derived B cells from an individual who had received an influenza vaccine 7 days prior to pan-B cell purification (7). The second human sample (Individual2) arises from blood-derived RBD-specific IgD-negative B cells pooled from different time points from a convalescent donor vaccinated with the SARS-CoV-2 spike protein (25). The other three human samples (Individual3-5) are part of a larger dataset that contains BCR sequences from various time points and tissues (26). From this dataset, we used three samples of blood-derived plasmablasts isolated 28 days after SARS-CoV-2 mRNA

vaccination. After processing and analyzing all datasets with 10x Genomics' Cell Ranger and the open-source R package Platypus (27), we obtained over 38,000 cells containing one heavy and one light chain. All repertoires exhibited clonal expansion for IgM, IgA, and IgG isotypes, thereby providing a comprehensive collection of repertoires to explore how PLMs can describe B cell selection (Figures 1B, S1, S2).

It was recently demonstrated that general PLM RLs could be employed to suggest mutations that improve antigen binding affinity by supplying full-length antibodies as input (20). We first questioned the extent to which the input sequences' contextual information influences downstream PLM-likelihood values by calculating SPs for each antibody sequence from three input sources: 1) the full VDJ sequence for maximum contextual information (full-VDJ) 2) the CDR3 residues in the VDJ sequence for medium contextual information (CDR3-from-VDJ), and 3) only the CDR3 sequence for the minimum contextual information (CDR3-only) (Figure 1C).

We began by employing the two general PLMs ESM-1b (12) and ProtBERT (13,16) as well as the two antibody-specific PLMs Ablang (18) and Sapiens (21) on the heavy and light chain sequences from all input sources for all samples. Next, we calculated the correlation between SPs from the three input sources (Figures 1D, S3A). We observed no correlation between the SPs from the CDR3-only to either CDR3-from-VDJ and full-VDJ sources for all samples (average r^2 = 0.049) . However, a correlation was observed when comparing the SPs from the sources full-VDJ to CDR3-from-VDJ (average r^2 = 0.407). This correlation was especially prominent in the antibody-specific PLMs for the human samples (average r^2 = 0.632) and was also observed when calculating the correlation for the heavy and light chains separately (Figure S3B). Together, these results recapitulate the ability of PLMs to capture long-range sequence interactions (12,13,16,21) and highlight the importance of the full-length antibody sequence in determining SPs.

SPs from different PLMs were marginally correlated
Different PLMs have been demonstrated to influence immune receptor representations (6,19). We therefore investigated how several general and antibody-specific PLMs correlated on in vivo antibody repertoire data for the three different input sources (Figure 2A). For the human samples, these SPs were slightly correlated across all models (average r^2 =0.476), and this correlation increased significantly when more contextual information was provided as input source (CDR3-from-VDJ average r^2 = 0.578 and full-VDJ average r^2 = 0.734). We observed the highest correlation between the antibody-specific PLMs (Ablang and Sapiens) when using the full-VDJ input sequences of the human samples (average r^2 = 0.802). Overall correlations were lower for the mouse samples (average r^2 = 0.328) and did not always increase when providing more contextual information. For the mouse samples, we observed the highest correlation between the two general PLMs (ProtBERT and ESM-1b) when using the full-VDJ input sequence (average r^2 = 0.749). The trend that general PLMs had the highest correlation also held true when analyzing only the light chains (Figure S4). Based on these findings and the more prominent role the heavy chain plays in antigen binding and structural properties (3), we decided to consider only the SPs of the full-VDJ heavy chain sequences for the rest of the analysis.

After observing the major contribution that the full-length antibody sequence plays in computed SPs (Figure 1), we questioned whether certain V genes were routinely deemed as more likely and whether this was consistent when using different PLMs. We therefore stratified SPs by V-gene subfamilies, which demonstrated a bias toward certain V-genes (Figure 2B). For both

the general PLMs, mouse sequences belonging to the IGHV1 family showed a relatively higher SP than other V-gene subfamilies (average ESM-1b SP of -0.188 v -0.214 and ProtBERT SP of -0.159 v -0.164, respectively). This contrast was reversed for the human samples, here sequences belonging to the IGHV1 and IGHV4 families showed a lower SP for ESM-1b in comparison to sequences from the other V-gene subfamilies (average SP of -0.202 v -0.180, respectively). No significant V-gene bias was observed with ProtBERT and the antibody-specific PLMs for the human samples. However, the antibody-specific PLM Sapiens showed a clear V-gene bias for the mouse sequences, with the IGHV1 family showing the lowest SP and IGHV7 the highest (average SP of -0.610 v -0.412, respectively). This observed V-gene bias with Sapiens in the mouse but not in the human samples is surprising considering Sapiens was trained solely on human antibody sequences. Together, these findings demonstrate the importance of model selection when using PLM likelihoods to engineer antibodies.

Repertoire SPs correlated with isotype usage and SHM but not clonal expansion.
PLMs and associated likelihoods have recently demonstrated the ability to contextualize properties of antibodies such as germline gene usage and degree of SHM (16), but such analyses have not yet been performed to investigate selection within entire repertoires at single-cell resolution. We, therefore, questioned whether PLM-based likelihoods were correlated to certain signatures of B cell selection in the various immunization and infection settings. As the majority of training data for antibody-specific PLMs arises from the human IgM isotype (28), we hypothesized that the SPs corresponding to IgM B cells would be higher than other isotypes.

While we indeed found that the IgM isotype in human repertoires corresponds to significantly higher SP values than IgG and IgA for antibody-specific PLMs, we additionally observed that this was also true for general PLMs despite being trained on general protein corpora (average SP of -0.183 v -0.232, respectively) (Figures 3A, S5A). As Sapiens is exclusively trained on human antibodies, we questioned whether SPs of murine repertoire would demonstrate more comparable SPs between isotypes. SPs from both Sapiens and Ablang were higher for murine IgM BCRs compared to IgA and IgG (average SP of -0.314 v -0.439, respectively), however this was not the case for both general PLMs. Together, these findings suggest that using either general or antibody-specific PLMs for antibody engineering can bias proposed mutations towards IgM-like antibodies.

We next leveraged the single-cell nature of the repertoire datasets to question whether the degree of clonal expansion correlated with SPs. We hypothesized that antibodies deemed more evolutionarily favorable may correspond to some inherent selection bias, and thereby have relatively larger degrees of clonal expansion. We computed the relative expansion within each repertoire and related this to the SPs for the four PLMs. We observed no major correlation between clonal expansion and SPs in humans and mice for both the general and antibody-specific PLMs (average r^2 = -0.067) (Figures 3B, S5B). Finally, as previous studies have demonstrated that PLM-based embeddings are sensitive to the amount of SHM (16,17), we finally questioned whether the amount of SHM correlated with SPs. We observed a negative trend between SP and the extent of SHM for the human samples (average r^2 = -0.692) (Figures 3C, S5C). This negative correlation increased remarkably when calculating SP with antibody-specific PLMs (average r^2 = -0.781), in which case the mouse samples also showed a negative trend (average r^2 = -0.422). Taken together, these findings reveal trends between repertoire features and SPs, suggesting a correlation between PLM-derived likelihoods and natural B cell selection.

SHM coincides with RLs

Thus far, we have explored the relationship between SHM and SP on the level of the repertoire. However, SHM occurs within a lineage-specific context, thereby motivating us to investigate how PLM-based likelihoods can infer or predict features of SHM on the level of the individual clone. We therefore constructed lineage trees using the Levenshtein distance to represent the evolutionary trajectory of SHM within each clone (Figures 4A, 4B). For the human samples, we observed that sequences closer to the germline had an overall higher SP (average r^2 = -0.523), this trend was less pronounced in the mice samples (average r^2 = -0.205) (Figures 4C, S6). This observation is in line with the repertoire-wide results of SHM count. We repeated this analysis for trees constructed using a maximum parsimony algorithm and obtained comparable results (Figure S7).

Next, we focused on the substitutions along the edges of the trees and the corresponding RL rank of those mutating positions. Edges in the trees usually represented a mutation toward one of the most likely residues at that position, except for the most likely (Figure 4D). Ablang substitution ranks were on average the highest (Figure 4E). To investigate the predictability of the location of SHM, we compared the original RL ranks of the mutating residues with the non-mutating conserved residues along the edges. Both the conserved and the mutating residues were generally at the highest rank. However, the ranks of mutating residues were more skewed and a t-test revealed that mutating residues have a significantly lower RL rank than non-mutating residues (Figure 4F). These results became more evident with the Ablang RL ranks. Comparable results were obtained when investigating the actual likelihood instead of the rank; mutating residues showed a lower RL than conserved residues and Ablang amplified this difference in comparison to ESM-1b (Figures 4G, 4H). Together, these results indicate that PLM-based likelihoods negatively correspond with reconstructed B cell evolution, as both SPs and RLs decrease along the edges of the trees. From the mutating residues, we can conclude that RLs can predict, to some extent, to what amino acid SHM will mutate. However, it is challenging to predict the position of SHM with RL alone, as both the mutating and non-mutating residues along the edges have comparable likelihoods and ranks.

SPs were correlated with functional features of antibodies

Having observed that SPs correlate with B cell repertoire features, we next questioned whether this relationship would also be reflected on a functional level. To this end, for the OVA-immunized mouse dataset, we considered OVA specificity labels as tested by ELISA for the most abundant sequences in the 177 most expanded IgG clones (9). A high degree of stochasticity in antigen binding was previously reported, as binding and non-binding clones were evenly distributed at all levels of expansion in the repertoire. For the human dataset of Kim *et al.* (Individual3-5 here), antigen specificity to SARS-CoV-2 S was tested by ELISA on 2,099 recombinant monoclonal antibodies derived from eight donors (26). These antibodies were generated from expanded clones in lymph node samples at seven and fifteen weeks post-vaccination. From these antibodies, 71.6% were shown to bind to the spike (S)-protein. We questioned whether antigen-binding clones are indeed stochastic, or whether SPs could be used to predict the selection of binding clones and therefore aid in the discovery of therapeutic antibodies.

We observed a significantly higher ESM-1b SP for binder compared to non-binder antibodies in the mouse dataset (average SP of -0.187 v -0.204, respectively) (Figure 5A). In contrast, Sapiens SPs of the mouse antibodies showed to be significantly higher for non-binders than binders (average SP of -0.545 v -0.577, respectively) (Figure S8A). As Sapiens was trained

purely on human antibody sequences, it is possible that less accurate likelihood predictions are generated on mouse antibodies. For the human antibodies, SPs calculated with all four PLMs were significantly higher for binders than for non-binders (average SP of -0.222 v -0.236, respectively) (Figure 5A, Figure S8C). These results suggest that SPs may capture features of in vivo antigen-specificity in the context of immunization.

It was previously demonstrated that antibody affinity was related to RLs in in vitro engineering efforts (20). We therefore questioned whether this relationship was also present in the context of in vivo B cell selection. For 58 of the OVA-specific antibodies from the mouse dataset, the affinity to their cognate antigen was previously measured using biolayer interferometry (BLI) (9). No correlation was found between binding affinity (determined by the dissociation constant (Kd)), clonal expansion, and the amount of SHM. For the human dataset of Kim *et al.* (26), binding affinity to the S-protein was measured with BLI for 43 antibodies derived from clonally related plasmablasts and bone marrow PCs from seven individuals. In our analysis, we observed no correlation between binding affinity and SPs for all four PLMs for the mice dataset (Figure 5B, Figure S8B). For the human data, a minor correlation was observed for all PLMs (average $r^2 = 0.200$), with the highest correlation for ESM-1b ($r^2 = 0.378$) (Figure 5C, Figure S 8D).

In addition to their polyclonal affinity analysis, Neumeier et al. (9) investigated antigen binding on the monoclonal level by measuring the affinity (BLI) of the sequences in the largest binding IgG clone of Mouse1. Congruent to the polyclonal analysis, they observed no correlation between the expansion of intraclonal sequence variants and binding affinity. Since we concluded that distance to the germline was in direct correlation with SP for the human data, we questioned how this would relate to binding affinity. To this end, we calculated the heavy chain SPs of these monoclonal sequences and constructed a lineage tree based on both the heavy and light chains (Figures 5D, 5E). We detected a positive correlation between ESM-1b SP and Kd values ($r^2 = 0.453$) (Figure 5F), thereby suggesting that antibodies with higher affinities correspond to lower SPs. Additionally, variants with the weakest binding affinity were shown to be closest to the germline sequence (Figure 5E). Taken together, these results indicate that SPs correlate with binding affinity on both the polyclonal and monoclonal level.

Discussion
Inspired by the work on in vitro antibody engineering performed by Hie et al. (20), we aimed to explore the relationship between PLM-based likelihoods and in vivo features of B cell selection and evolution. We utilized general and antibody-specific PLMs on single-cell V(D)J sequencing data of humans and mice and discovered that SPs are correlated with various features of B cell selection, such as V-gene usage, isotype, and antigen specificity. These SPs also showed a correlation with features of B cell evolution such as SHM and affinity maturation. Binding affinity data revealed an overall lower SP for antibodies with a higher affinity in both the human and mice datasets. This finding is in direct contrast with the results of Hie et al. where PLM-suggested mutations increased the binding affinity (20). This discrepancy could be due to the difference between in vitro and in vivo settings, as in vivo B cell selection involves a number of complex interactions such as T cell help, germinal center formation, antigen presentation of follicular dendritic cells, and B cell migration. Another possibility is that ESM-1b is increasing the stability of the antigen binding residues since most of the proposed mutations occurred in the framework regions which are generally less mutated in vivo compared to the CDR regions (29,30). In our exploitation of this discovery, we uncovered additional aspects of in vivo B cell selection and evolution influenced by PLMs. Labels on antigen specificity revealed SPs to be

significantly higher for binding than for non-binding antibodies in both the mouse dataset and the human COVID-19 dataset from Kim et al. (26). However, this difference in SP is minor and warrants further experimental exploration given that PLMs do not consider antigen-specificity during training. The mouse dataset is from BALB/c mice housed under pathogen-free conditions, thus most expanded clones are expected to be OVA-binding. This is the case for the most expanded IgG clones, but highly expanded non-binding IgM and IgA clones were also detected. This bystander activation could be a result of age- or autoimmune-associated B cells which are observed in inbred mice strains in previous findings (31,32).

When engineering an antibody, solely altering the CDR3 region instead of the full V(D)J might be desirable to maintain protein stability while focusing on the most significant sequence region for antigen binding. However, our results indicate that PLMs are dependent on the long-range interactions of the full V(D)J sequence to extract biologically meaningful features of the BCR repertoire. Additionally, we found antibody-specific PLMs to have a higher correlation with features of B cell selection and evolution than general PLMs. A limitation of the PLMs used here is the lack of cross-chain representation. The pairing of the heavy- and light chain is crucial for antigen binding, which shapes B cell evolution. It was recently demonstrated that training a PLM on natively paired chains and fine-tuning the pre-trained ESM-2 with native pairing improved the models' performance on antigen specificity classification tasks (33). Another consideration when using these PLMs is selection bias in the training data. In these databases, most antibody sequences closely resemble germline genes (34). This explains the inverse correlation between SP and distance to the germline. Pre-training antibody-specific PLMs with SHM as an objective function could improve the learning of B cell evolution. Wang et al. (35) showed that incorporating antibody-specific evolution mechanisms such as germline prediction and mutation position prediction benefits antibody representation learning. Lastly, including the antigen and structural information in the model architecture might further improve the PLMs, as recently demonstrated by Shanker et al. (24).

Based on our lineage trees, we observe that PLMs routinely rank SHM as one of the most likely mutations but that predicting the location of the mutating residue is more challenging. Mutating residues generally have a slightly lower likelihood than conserved residues, although the inherent undersampling of single-cell immune repertoire sequencing experiments makes it challenging to conclusively label conserved and mutating residues. Furthermore, epistatic mutations further complicate our results, as the presence of multiple mutations influences the likelihood of the other residues. Edges covering multiple mutations could be due to under-sampling since typically one base pair mutates per round in the germinal center (36). Computational models of SHM prediction are usually based on k-mer subsequences from 3- to 7-mers (30,37). However, studies have suggested that a longer k-mer better captures SHM as it considers a wider neighborhood (38–40). For this reason, PLM-based RLs are a valuable option for SHM prediction, as this considers the context of the entire input sequence. Factors such as activation-induced cytidine deaminase and polymerase hotspots, structural features, and G-content could improve SHM prediction (38).

Together, our results emphasize the ability of PLMs to represent the unique features of in vivo B cell selection and evolution. Importantly, our results demonstrate how various features, such as the model, training data, and contextual information, can dramatically influence PLM output likelihoods. While the promise of leveraging PLMs for in vitro antibody engineering has been demonstrated, further work is needed to fully leverage PLMs to predict functional features of antibody selection in vivo.

Figure 1. Contextual information influences SPs of antibody repertoires. A) Four publicly available single-cell V(D)J sequencing datasets were used to obtain paired heavy and light chain BCR sequences for five mice and five human samples following immune challenges. I = Individual, M = Mouse. Created in BioRender. B) Total cell count (top) and distribution of clonal expansion (bottom) per sample. Each section corresponds to a unique clone, and the size corresponds to the fraction of cells relative to the total repertoire. The black color highlights the fraction of clones containing one cell. C) Schematic overview of the three input sources; 1: full VDJ as input and full VDJ used to calculate SP, 2: full VDJ as input but only CDR3 used to calculate SP, 3: CDR3 as input and CDR3 used to calculate SP. Created in BioRender. D) Pearson's Correlation between the SP based on the input sources for two representative PLMs.

Figure 2. Correlation between SPs calculated with four different PLMs. A) Pearson correlation between the SP calculated with the different PLMs for each of the three input sources. B) SPs calculated with different PLMs for mice (left) and human (right) samples colored by the V-gene family.

Figure 3. Correlation between SPs and features of B cell repertoire evolution. A) Distribution of SPs of BCRs from certain isotypes for a general PLM (left) and an antibody-specific PLM (right). T-test significance: *** = adjusted p-value below 0.001, NS = non-significant. B) Pearson Correlation between normalized clonal expansion (number of cells per clonotype divided by the sample size) and SP for ESM-1b (left) and Ablang (right). C) Pearson Correlation between the amount of SHM (hamming distance from the germline) and SP for ESM-1b (left) and Ablang (right).

Figure 4. SHM coincides with RLs. A&B) Representative lineage trees colored by ESM-1b heavy chain SP. Numbers in the nodes indicate the number of cells. C) Pearson Correlation between ESM-1b SP and the total edge length to the germline (Levenshtein distance) for each sequence in all trees. D) The RL ranks of the substitutions along the edges of the lineage trees with ESM-1b (left) and Ablang (right). The average rank is used for edges with multiple substitutions. E) Mean substitution RL rank for each sample (dots) and average of all samples (bars) per PLM. F) Difference in RL rank between conserved and mutating residues with ESM-1b (left) and Ablang (right). G) The RLs of the mutating original and conserved residue(s) along the edges of the lineage trees for ESM-1b (left two) and Ablang (right two). H) Difference in RL between conserved and mutating residues with ESM-1b (left) and Ablang (right). T-test significance: **** = adjusted p-value below 0.0001

Figure 5. SP correlation with antigen-specificity and binding affinity. A) Polyclonal heavy chain ESM-1b SP and ELISA determined antigen-specificity against Ovalbumin (left) and SARS-Cov-2 S-protein (right). T-test significance: * = p ≤ 0.05; ** = p ≤ 0.01. B) Spearman Correlation between polyclonal binding affinity against Ovalbumin and heavy chain ESM-1b SP for three mouse samples. C) Spearman Correlation between polyclonal binding affinity against SARS-Cov-2 S protein and heavy chain ESM-1b SP for seven individuals from Kim et al. (26) D) Lineage tree of largest IgG clone of Mouse1 colored by heavy chain ESM-1b SP. E) Lineage tree of largest IgG clone of Mouse1 colored by binding affinity to Ovalbumin. F) Spearman Correlation between monoclonal binding affinity to Ovalbumin and heavy chain ESM-1b SP and for the largest IgG clones of Mouse 1. The color indicates Levenshtein distance to the germline.

Supplementals

Figure S1. Clonal expansion of all human samples (left) and mouse samples (right) colored on isotype. Ranked bar plots depict the thirty-five most expanded clones of each sample.

Figure S2. Isotype distribution per sample. I = Individual, M = Mouse.

Figure S3. Input source correlations. A) The Pearson Correlation of SPs between the three sources of input for four different PLMs. B) The Pearson Correlation of SPs between the three sources of input for four different PLMs separated by heavy and light chains.

Figure S4. Pearson Correlation between SPs calculated with different PLMs for each of the three input sources separated by heavy and light chains.

Figure S5. Correlation between SPs and features of B cell repertoire evolution. A) Distribution of SPs of BCRs from certain isotypes for a general PLM (left) and an antibody-specific PLM (right). T-test significance: *** = adjusted p-value below 0.001, NS = non-significant. B) Pearson Correlation between normalized clonal expansion (number of cells per clonotype divided by the sample size) and SP for ProtBERT (left) and Sapiens (right). C) Pearson Correlation between the amount of SHM (hamming distance from the germline) and SP for ProtBERT (left) and Sapiens (right).

Figure S6. Correlation between SP and the total edge length (Levenshtein distance) to the germline for each heavy chain VDJ sequence in the lineage trees of all samples for three PLMs.

Figure S7. Phylogenetic analysis of the clonal lineages constructed with a maximum parsimony algorithm. A) Representative plots of the lineage trees colored by ESM-1b full-VDJ SP. White nodes represent intermediate nodes recovered by the phylogenetic algorithm. B) Correlation

between SP of all PLMs and the total edge length (Levenshtein distance) to the germline for each sequence in all trees.

Figure S8. Spearman Correlation of SP with polyclonal antigen-specificity and binding affinity. A) SP and antigen-specificity against Ovalbumin. B) Correlation between binding affinity and SPs for mouse samples. C) SP and antigen-specificity against Sars-COV-2 S protein. D) Correlation between binding affinity and SP for 7 individuals (sample IDs correspond to those of Kim et al.(26)). (T-test significance: ns = $p > 0.05$; * = $p \leq 0.05$; ** = $p \leq 0.01$; *** = $p \leq 0.001$; **** = $p \leq 0.0001$)

Methods
Code to reproduce all results in this manuscript can be found in the following GitHub repository: https://github.com/dvginneken/PLM_Likelihoods

Data Collection
For this manuscript, four publicly available datasets were used. The mouse dataset, as described in Neumeier et al. (9), was downloaded from the Platypus Database (https://alexyermanos.github.io/Platypus/PlatypusDB_index.html) with project ID "neumeier2021b". The dataset corresponding to Individual1, as described in Horns et al. (7), was also downloaded from the Platypus Database with project ID "horns2020a". Since this dataset consists of multiple technical replicates, only the sample "Influenza.vac.11.12.human.S1" was used here. The dataset corresponding to Individual2, as described in Bruhn et al. (25), was downloaded from the NCBI Sequence Read Archive using SRA Toolkit with ID SRR24140776. This data was then processed with the CellRanger VDJ pipeline v8.0.0 from 10x Genomics. The dataset corresponding to Individual3-5, as described in Kim et al. (26), was also downloaded from SRA and processed with the CellRanger VDJ pipeline. SRR IDs used were: SRR17729703 for Individual3; SRR17729692 for Individual4; SRR17729726 for Individual5.

Repertoire Analysis
CellRanger output from all datasets was further processed with the Platypus package (version 3.6.0) in R to obtain BCR repertoire information such as clonotypes, expansion, germline sequences, isotype, and v/d/j-gene usage (27). We applied the following parameters to the VDJ_build() function: trim.germlines = T, remove.divergent.cells = T, complete.cells.only = T. These parameters trim the germline to the V(D)J region, remove cells with more than 1 V(D)J transcript, and remove cells missing either a heavy or light chain transcript. Next, cells without an annotated germline, heavy chain C-gene, or duplicated barcode were removed for further analysis. Somatic hypermutations were quantified by aligning each sequence to its corresponding germline and calculating the hamming distance.

Protein Language Models
The following four pre-trained PLMs were used in this manuscript: ESM-1b (12), ProtBERT (13), Ablang (18), and Sapiens (21) using the Transformers package (version 4.36.1) in Python. All the heavy and light chain amino acid V(D)J and CDR3 sequences were used as input. For Ablang (18) and Sapiens (21), the separate heavy and light chain model was used corresponding to the chain of the input sequence. As output from these models, we got the per-sequence pseudolikelihood and a probability matrix of the per-residue likelihood. The per-sequence pseudolikelihood (SP) was calculated by summing up the log-scaled probability of every residue and dividing this by the sequence length. For input source CDR3-from-VDJ, the entire V(D)J sequence was used as input for the PLM, but only the CDR3 sequence was used to calculate the pseudolikelihood.

Constructing Lineage Trees
Phylogenetic networks of the clonal lineages were created by pasting together the heavy and light chain of each sequence and performing an algorithm similar to a minimum spanning tree. We first calculate a distance matrix based on the Levenshtein distance. Next, we place the germline node on top of the tree and iteratively add nodes of unique sequences to the tree with a minimum distance to the current nodes in the tree. When there is a tie of the minimum distance, the tie will be resolved hierarchically. First, the node will be attached to the most

expanded node. If this is still a tie, the node will be attached to the node with the smallest Levenshtein distance or number of edges to the germline. If a tie remains, the node will be attached randomly. Regarding the maximum parsimony trees in the supplementary materials, the Phangorn package (version 2.11.1) in R was used (41).

Analysis of SHM in Lineage Trees
Substitutions along the edges of the lineage trees were identified by retrieving the unique sequences of all nodes of all trees except the germlines. If the sequence before the edge (seq1) and the sequence after the edge (seq2) had the same length, differential positions were identified. Next, a PLM probability matrix was computed for seq1 (the probability of each amino acid per position). For each differential position, the probabilities were ranked in descending order and the rank of the amino acid at this position in seq2 was selected as substitution rank. If there were multiple differential positions for an edge, the average was computed as substitution rank. For the predictability of the SHM location, we did the same workflow. However, we selected the rank of the amino acid in seq1 instead of seq2. In addition to the rank, we also analyzed the average probability (likelihood) of the differential- and identical positions of seq1.

Acknowledgments
We thank Victor Greiff for his insightful feedback on the manuscript, which greatly improved its clarity and quality.

Ethics statement
The authors have no competing interests.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Eisen HN, Sykulev Y, Tsomides TJ. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv Protein Chem. 1996;49:1–56.

2. Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3628–32.

3. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000 Jul;13(1):37–45.

4. Eisen HN, Siskind GW. Variations in affinities of antibodies during the immune response. Biochemistry. 1964 Jul;3(7):996–1008.

5. Miho E, Yermanos A, Weber CR, Berger CT, Reddy ST, Greiff V. Computational Strategies for Dissecting the High-Dimensional Complexity of Adaptive Immune Repertoires. Front Immunol [Internet]. 2018 Feb 21 [cited 2024 Sep 26];9. Available from: https://pubmed.ncbi.nlm.nih.gov/29515569/

6. Agrafiotis A, Neumeier D, Hong KL, Chowdhury T, Ehling R, Kuhn R, et al. Generation of a single-cell B cell atlas of antibody repertoires and transcriptomes to identify signatures associated with antigen specificity. iScience. 2023 Mar 17;26(3):106055.

7. Horns F, Dekker CL, Quake SR. Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics. Cell Rep. 2020 Jan 21;30(3):905–13.e6.

8. Reddy ST, Ge X, Miklos AE, Hughes RA, Kang SH, Hoi KH, et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol. 2010 Sep;28(9):965–9.

9. Neumeier D, Yermanos A, Agrafiotis A, Csepregi L, Chowdhury T, Ehling RA, et al. Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells. Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2113766119.

10. Mhanna V, Bashour H, Lê Quý K, Barennes P, Rawat P, Greiff V, et al. Adaptive immune receptor repertoire analysis. Nature Reviews Methods Primers. 2024 Jan 25;4(1):1–25.

11. Mathew NR, Jayanthan JK, Smirnov IV, Robinson JL, Axelsson H, Nakka SS, et al. Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells. Cell Rep. 2022 Nov 29;41(9):111764.

12. Rives A, Meier J, Sercu T, Goyal S, Lin Z, Liu J, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc Natl Acad Sci U S A [Internet]. 2021 Apr 13;118(15). Available from: http://dx.doi.org/10.1073/pnas.2016239118

13. Elnaggar A, Heinzinger M, Dallago C, Rehawi G, Wang Y, Jones L, et al. ProtTrans: Toward Understanding the Language of Life Through Self-Supervised Learning. IEEE Trans Pattern

Anal Mach Intell. 2022 Oct;44(10):7112–27.

14. Lin Z, Akin H, Rao R, Hie B, Zhu Z, Lu W, et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science. 2023 Mar 17;379(6637):1123–30.

15. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021 Aug;596(7873):583–9.

16. Leem J, Mitchell LS, Farmery JHR, Barton J, Galson JD. Deciphering the language of antibodies using self-supervised learning. Patterns (N Y). 2022 Jul 8;3(7):100513.

17. Ruffolo JA, Gray JJ, Sulam J. Deciphering antibody affinity maturation with language models and weakly supervised learning [Internet]. 2021 [cited 2024 Sep 26]. Available from: http://arxiv.org/abs/2112.07782

18. Olsen TH, Moal IH, Deane CM. AbLang: an antibody language model for completing antibody sequences. Bioinform Adv. 2022 Jun 17;2(1):vbac046.

19. Singh R, Im C, Qiu Y, Mackness B, Gupta A, Sorenson T, et al. Learning the Language of Antibody Hypervariability [Internet]. bioRxiv. 2024 [cited 2024 Sep 26]. p. 2023.04.26.538476. Available from: https://www.biorxiv.org/content/10.1101/2023.04.26.538476v2.abstract

20. Hie BL, Shanker VR, Xu D, Bruun TUJ, Weidenbacher PA, Tang S, et al. Efficient evolution of human antibodies from general protein language models. Nat Biotechnol. 2024 Feb;42(2):275–83.

21. Prihoda D, Maamary J, Waight A, Juan V, Fayadat-Dilman L, Svozil D, et al. BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. MAbs. 2022 Jan-Dec;14(1):2020203.

22. Ruffolo JA, Chu LS, Mahajan SP, Gray JJ. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat Commun. 2023 Apr 25;14(1):2389.

23. Hie BL, Yang KK, Kim PS. Evolutionary velocity with protein language models predicts evolutionary dynamics of diverse proteins. Cell Syst. 2022 Apr 20;13(4):274–85.e6.

24. Shanker VR, Bruun TUJ, Hie BL, Kim PS. Unsupervised evolution of protein and antibody complexes with a structure-informed language model. Science. 2024 Jul 5;385(6704):46–53.

25. Bruhn M, Obara M, Salam A, Costa B, Ziegler A, Waltl I, et al. Diversification of the VH3-53 immunoglobulin gene segment by somatic hypermutation results in neutralization of SARS-CoV-2 virus variants. Eur J Immunol. 2024 Jul;54(7):e2451056.

26. Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022 Apr;604(7904):141–5.

27. Cotet TS, Agrafiotis A, Kreiner V, Kuhn R, Shlesinger D, Manero-Carranza M, et al. ePlatypus: an ecosystem for computational analysis of immunogenomics data.

Bioinformatics [Internet]. 2023 Sep 2;39(9). Available from:
http://dx.doi.org/10.1093/bioinformatics/btad553

28. Olsen TH, Boyles F, Deane CM. Observed Antibody Space: A diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 2022 Jan;31(1):141–6.

29. Ovchinnikov V, Louveau JE, Barton JP, Karplus M, Chakraborty AK. Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies. Elife [Internet]. 2018 Feb 14;7. Available from: http://dx.doi.org/10.7554/eLife.33038

30. Yaari G, Vander Heiden JA, Uduman M, Gadala-Maria D, Gupta N, Stern JNH, et al. Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data. Front Immunol. 2013 Nov 15;4:358.

31. Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011 Aug 4;118(5):1294–304.

32. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c$^+$ B-cell population is important for the development of autoimmunity. Blood. 2011 Aug 4;118(5):1305–15.

33. Burbach SM, Briney B. Improving antibody language models with native pairing. Patterns (N Y). 2024 May 10;5(5):100967.

34. Olsen TH, Moal IH, Deane CM. Addressing the antibody germline bias and its effect on language models for improved antibody design. Bioinformatics [Internet]. 2024 Nov 1;40(11). Available from: http://dx.doi.org/10.1093/bioinformatics/btae618

35. Wang D, Ye F, Zhou H. On Pre-trained Language Models for Antibody [Internet]. 2023 [cited 2024 Sep 27]. Available from: http://arxiv.org/abs/2301.12112

36. McKean D, Huppi K, Bell M, Staudt L, Gerhard W, Weigert M. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 1984 May;81(10):3180–4.

37. Cui A, Di Niro R, Vander Heiden JA, Briggs AW, Adams K, Gilbert T, et al. A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Ig Sequencing Data. J Immunol. 2016 Nov 1;197(9):3566–74.

38. Tang C, Krantsevich A, MacCarthy T. Deep learning model of somatic hypermutation reveals importance of sequence context beyond hotspot targeting. iScience. 2022 Jan 21;25(1):103668.

39. Zhou JQ, Kleinstein SH. Position-Dependent Differential Targeting of Somatic Hypermutation. J Immunol. 2020 Dec 15;205(12):3468–79.

40. Spisak N, Walczak AM, Mora T. Learning the heterogeneous hypermutation landscape of immunoglobulins from high-throughput repertoire data. Nucleic Acids Res. 2020 Nov

4;48(19):10702–12.

41. Schliep KP. phangorn: phylogenetic analysis in R. Bioinformatics. 2011 Feb 15;27(4):592–3.